Biomolecular changes on mice caput femur after human recombinant erythropoietin administration
Keywords:Osteonecrosis, erythropoietin, osteocyte, osteoblast, BMP-2, VEGF, adipocyte
Osteonecrosis is a process of death of bone tissue which also causes disturbance in the bone’s blood vessel supply. Administration of recombinant human erythropoietin (rHuEPO) may affect cell proliferation by stimulating angiogenesis and it has been proven that cell proliferation during osteogenesis depends heavily on the formation of new blood vessels. Therefore, EPO has a role in bone regeneration.
This research is an experimental study using Randomized post-test control only group design. Rats were divided into 2 groups, P0 which received dexamethasone injection for 5 weeks and group P1 which received dexamethasone injection combined with rHuEpo for 5 weeks. On the last day of the fifth week, the femoral head of the rats were taken for assessment of VEGF (Vascular Endothelial Growth Factor), BMP-2 (Bone Morphogenic Protein-2), osteocytes, osteoblasts and adipocytes levels. The examination results were then analyzed by using SPSS.
From the immunohistochemical and histopathologic examination and further SPSS analysis, it is shown that the number of osteocyte in the femoral heads of rats injected with dexamethasone and rHuEpo were significantly higher than those injected with dexamethasone alone (p <0.05). This was also the case with the number of osteoblasts (p <0.05). The expression of BMP-2 and VEGF were also significantly higher in rats injected with dexamethasone and rHuEPO (p <0.05). However, the number of adipocytes in the femoral heads of the rats injected with dexamethasone and rHuEpo were significantly lower than those injected with dexamethasone alone (p <0.05).
Administration of rHuEPO in rats induced with dexamethasone was shown to increase the number of osteoblast, osteocyte, BMP-2 expression, and VEGF, but the number of adipocyte was found to be lower than in rats injected with dexamethasone alone.
Beamer, B., Hettrich, C. and Lane, J. (2010) ‘Vascular endothelial growth factor: an essential component of angiogenesis and fracture healing.’, HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 6(1), pp. 85–94. doi: 10.1007/s11420-009-9129-4.
Chan, K. L. and Mok, C. C. (2012) ‘Glucocorticoid- Induced Management Avascular Bone Necrosis : Diagnosis and’, pp. 449–457.
Chung, FY; Lin SR; Tsai WC; Liu, H. (2005) ‘PPAR γ -2 AND BMPR2 GENES WERE SIGNIFICANTLY DIFFERENTIALLY EXPRESSED IN PERIPHERAL BLOOD ABSTRACT INTRODUCTION : DISCUSSION : METHODS : Poster No : 1307’, Orthopaedic Research Society, p. 2005.
Drescher, W. et al. (2011) ‘Steroid-related osteonecrosisan update’, Nephrology Dialysis Transplantation, 26(9), pp. 2728–2731. doi: 10.1093/ndt/gfr212.
Drescher W, Varoga D, Petersen W, Tillmann B, P. T. (2003) ‘EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN STEROID RELATED AVASCULAR NECROSIS OF THE HUMAN FEMORAL HEAD Poster No . 572 • 56th Annual Meeting of the Orthopaedic Research Society’, (449), p. 572.
Hendrik, J. and Rölfing, D. (2014) ‘The effect of erythropoietin on bone The effect of erythropoietin on bone’, 85(353).
Hiram-Bab, S. et al. (2015) ‘Erythropoietin directly stimulates osteoclast precursors and induces bone loss’, FASEB Journal, 29(5), pp. 1890–1900. doi: 10.1096/ fj.14-259085.
Hiram-Bab, S., Neumann, D. and Gabet, Y. (2017) ‘Erythropoietin in bone – Controversies and consensus’, Cytokine, 89, pp. 155–159. doi: 10.1016/j. cyto.2016.01.008.
Holstein, J. H. et al. (2011) ‘Erythropoietin stimulates bone formation , cell proliferation , and angiogenesis in a femoral segmental defect model in mice’, Bone. Elsevier Inc., 49(5), pp. 1037–1045. doi: 10.1016/j. bone.2011.08.004.
Kaushik, A. P., Das, A. and Cui, Q. (2012) ‘Osteonecrosis of the femoral head: An update in year 2012’, World Journal of Orthopedics, 3(5), pp. 49–57. doi: 10.5312/ wjo.v3.i5.49.
Li, J. et al. (2017) ‘Erythropoietin facilitates the recruitment of bone marrow mesenchymal stem cells to sites of spinal cord injury’, Experimental and Therapeutic Medicine, 13(5), pp. 1806–1812. doi: 10.3892/etm.2017.4182.
Littlewood, T. and Macdougall, I. (2003) ‘Recombinant erythropoietin in clinical practice.’, Postgraduate medical journal, 79(933), pp. 367–376. doi: 10.1136/ pmj.79.933.367.
Liu, Y. et al. (2015) ‘Nonerythropoietic Erythropoietin- Derived Peptide Suppresses Adipogenesis, Inflammation, Obesity and Insulin Resistance’, Scientific Reports, 5. doi: 10.1038/srep15134.
Lombardero, M. and Scheithauer, B. W. (2011) ‘Erythropoietin ’:, pp. 41–53. doi: 10.1159/000322975.
Malizos, K. N. et al. (2007) ‘Osteonecrosis of the femoral head: Etiology, imaging and treatment’, European Journal of Radiology, 63(1), pp. 16–28. doi: 10.1016/j. ejrad.2007.03.019.
McGee, S. J. et al. (2012) ‘Effects of erythropoietin on the bone microenvironment.’, Growth factors (Chur, Switzerland), 30(1), pp. 22–8. doi: 10.3109/08977194.2011.637034.
Powell, C. et al. (2010) ‘Autoimmunity Reviews Steroid induced osteonecrosis : An analysis of steroid dosing risk’, Autoimmunity Reviews. Elsevier B.V., 9(11), pp. 721–743. doi: 10.1016/j.autrev.2010.06.007.
Raida, M. et al. (2005) ‘Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis’, Journal of Cancer Research and Clinical Oncology, 131(11), pp. 741–750. doi: 10.1007/s00432-005-0024-1.
Razzouk, S. and Sarkis, R. (2012) ‘BMP-2: biological challenges to its clinical use.’, The New York state dental journal, 78(5), pp. 37–9.
Seamon, J. et al. (2012) ‘The Pathogenesis of Nontraumatic Osteonecrosis’, 2012(Figure 1). doi: 10.1155/2012/601763.
Steinert, S. et al. (2008) ‘Differential expression of cancerrelated genes by single and permanent exposure to bone morphogenetic protein 2’, Journal of Cancer Research and Clinical Oncology, 134(11), pp. 1237–1245. doi: 10.1007/s00432-008-0396-0.
Sun, H. et al. (2012) ‘Erythropoietin Modulates the Structure of Bone Morphogenetic Protein 2–Engineered Cranial Bone’, Tissue Engineering Part A, 18(19–20), pp. 2095–2105. doi: 10.1089/ten.tea.2011.0742.
Tang, T. T. et al. (2007) ‘Treatment of osteonecrosis of the femoral head with hBMP-2-gene-modified tissueengineered bone in goats.’, The Journal of bone and joint surgery. British volume, 89(1), pp. 127–129. doi:10.1302/0301-620X.89B1.18350.
Tripathy, S. K., Goyal, T. and Sen, R. K. (2015) ‘Management of femoral head osteonecrosis: Current concepts.’, Indian journal of orthopaedics, 49(1), pp. 28–45. doi: 10.4103/0019-5413.143911.
Users, T. (2015) ‘Guideline for Diagnostic and Treatment of Osteonecrosis of the Femoral Head’, Orthopaedic Surgery, 7(3), pp. 200–207. doi: 10.1111/os.12193.
Wang, L. et al. (2011) ‘BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line.’, Cancer biology & therapy, 11(5), pp. 457–63.
Wang, W. et al. (2012) ‘The effect of core decompression on local expression of BMP-2, PPAR-γ and bone regeneration in the steroid-induced femoral head osteonecrosis’, BMC Musculoskeletal Disorders. BMC Musculoskeletal Disorders, 13(1), p. 142. doi: 10.1186/1471-2474-13-142.
Wernike, E. et al. (2010) ‘Vegf incorporated into calcium phosphate ceramics promotes vascularisation and bone formation in vivo’, European Cells and Materials, 19, pp. 30–40. doi: vol019a04 [pii].
Xie, X., Wang, X. and Yang, H. (2015) ‘ScienceDirect Steroid-associated osteonecrosis : Epidemiology ,
pathophysiology , animal model , prevention , and potential treatments ( an overview )’, Journal of Orthopaedic Translation. Elsevier Ltd, pp. 1–13. doi: 10.1016/j.jot.2014.12.002.
Yeh, C. H. et al. (2009) ‘Different differentiation of stroma cells from patients with osteonecrosis: A pilot study’, Clinical Orthopaedics and Related Research, 467(8), pp. 2159–2167. doi: 10.1007/s11999-009-0803-0.
Zhang, W. et al. (2014) ‘VEGF and BMP-2 promote bone regeneration by facilitating bone marrow stem cell homing and differentiation’, European Cells and Materials, 27, pp. 1–12. doi: 10.22203/eCM.v027a01.
Zibis, A. H. et al. (2015) ‘Osteonecrosis of the femoral head -Diagnosis and management’, Precision Medicine, 2(868), pp. 1–8. doi: 10.14800/pm.868.